Both tirzepatide and retatrutide improve cardiovascular risk markers in type 2 diabetes, but longer follow-up studies are needed to confirm long-term heart protection for both drugs.
Dual vs triple agonistsTirzepatide (dual GIP/GLP-1) has proven CV benefits; retatrutide (triple GIP/GLP-1/glucagon) shows promising markers but awaits dedicated CV outcomes trials
What the researchers found
Both tirzepatide and retatrutide improve glycemia, HbA1c, body weight, lipid profiles, blood pressure, and renal parameters in type 2 diabetes patients. Tirzepatide has recent proven cardiovascular benefits from dedicated outcomes trials. Retatrutide data is more limited, coming from earlier-phase trials. Both drugs show promising CV risk marker improvement, but standardized long-term follow-up is needed, especially for retatrutide.
Why it matters
The incretin therapy landscape is evolving rapidly from single GLP-1 agonists to dual (tirzepatide) and triple (retatrutide) receptor agonists. Understanding how these multi-target drugs compare for cardiovascular protection helps clinicians and patients make informed treatment choices as more options become available.
The numbers in context
Review covered original RCTs from the last 10 years in adult human populations. Compared known data for retatrutide vs. tirzepatide.
How the study worked
Systematic review registered with PROSPERO (CRD42024507397). Included original RCTs from the last 10 years in English, conducted in adult human populations. Excluded cell/animal studies, case reports, reviews, and incomplete data. Seven studies assessed for bias using the Newcastle-Ottawa scale.
Who was studied
Adults with type 2 diabetes from randomized controlled trials
What this study cannot tell us
Only seven studies met inclusion criteria — limited evidence base especially for retatrutide. Heterogeneous study designs and follow-up periods. No direct head-to-head trials comparing tirzepatide to retatrutide. Long-term CV outcomes data not yet available for retatrutide. Assessment limited to metabolic surrogate markers rather than hard CV endpoints for retatrutide.
How to read the evidence
Rated moderate: registered systematic review but limited by only 7 studies, heterogeneous designs, and lack of direct head-to-head comparison.
When this study was published
Published in 2024. Captures early evidence for both drugs, with tirzepatide data more mature than retatrutide.
The bigger picture
The progression from single (GLP-1) to dual (GIP/GLP-1) to triple (GIP/GLP-1/glucagon) receptor agonists represents a major trend in diabetes pharmacology. Each additional target may add metabolic and cardiovascular benefits, but the evidence base needs to catch up.
Questions still open
- Will retatrutide's triple-agonist mechanism provide stronger CV protection than tirzepatide?
- Are the cardiovascular benefits independent of metabolic improvements?
- How do these drugs compare for patients without diabetes who have CV risk?
Common questions
Is tirzepatide good for the heart?
How does retatrutide compare to tirzepatide?
Read the original research
Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.
Pharmaceuticals (Basel, Switzerland), 17(10)
Citation
Salmen, Teodor; Potcovaru, Claudia-Gabriela; Bica, Ioana-Cristina; Giglio, Rosaria Vincenza; Patti, Angelo Maria; Stoica, Roxana-Adriana; Ciaccio, Marcello; El-Tanani, Mohamed; Janež, Andrej; Rizzo, Manfredi; Gherghiceanu, Florentina; Stoian, Anca Pantea. (2024). Evaluating the Impact of Novel Incretin Therapies on Cardiovascular Outcomes in Type 2 Diabetes: An Early Systematic Review.. Pharmaceuticals (Basel, Switzerland), 17(10). https://doi.org/10.3390/ph17101322